The 10 FDA-Approved Long-Term Treatments for MS
The following list includes the 10 disease-modifying therapies (DMTs) that are FDA-approved (at the time of this booklet’s printing) for the long-term treatment of MS.
Given via self-injection:
- Avonex® (interferon beta-1a), given weekly
- Betaseron® (interferon beta-1b), given every other day
- Copaxone® (glatiramer acetate), given daily or three-times weekly
- Extavia® (interferon beta-1b), given every other day
- Rebif® (interferon beta-1a), given three-times weekly
Given via intravenous (IV) infusion:
- Novantrone® (mitoxantrone), given every three months, although seldom prescribed due to serious health risks
- Tysabri® (natalizumab), given every four weeks
- Aubagio® (teriflunomide), taken daily
- Gilenya® (fingolimod), taken daily
- Tecfidera™ (dimethyl fumarate or DMF), taken twice daily
At the time of printing, the 10 drugs listed above were the only ones approved by the FDA for the long-term treatment of MS. However, several other drugs are under FDA review. These include: Plegridy™ (PEGylated interferon beta-1a), which is self-injected every two weeks; one or more generic versions of Copaxone® (listed above); and Lemtrada® (alemtuzumab), given via IV in annual courses. For more information on long-term treatments for MS and how to select the treatment that is right for you, please see MSAA’s S.E.A.R.C.H.™ program at mymsaa.org/ms-information/search.